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Abstract
Background: Diagnosis and treatment of latent tuberculosis infection (LTBI) is the most effective strategy to control
tuberculosis (TB) among patients with HIV infection. The tuberculin skin test (TST) was the only available method to
identify LTBI. The aim of the present work was to evaluate the usefulness of the interferon-gamma release assays
(IGRAs): QuantiFERON-tuberculosis (TB) Gold-In-Tube test (QFG) and T-SPOT.TB for the diagnosis of LTBI in a diverse
cohort of HIV-infected patients.
Methods: A prospective study was carried out in consecutive patients cared for in a single institution in Spain from
January 2009 to October 2010. IGRAs and TST were performed simultaneously. TST induration ≥ 5 mm was
considered positive.
Results: QFG, T-SPOT.TB and TST were performed in 373 subjects. Median CD4 cell count was 470/μl with a median
nadir of 150/μl. TST, QFG and T-SPOT.TB were positive in 13.3%, 7.5% and 18.5% cases respectively. Among 277
patients with neither past or current TB nor previous treatment for LTBI and who had TST results, a positive TST
result was obtained in 20 (7.2%) cases. When adding QFG results to TST, there were a total of 26 (8.6%) diagnoses
of LTBI. When the results of both IGRAs were added, the number of diagnoses increased to 54 (17.9%) (incremental
difference: 10.7% [95% confidence interval [CI]:5.3-16.2%] [p < 0.001]), and when both IGRAs were added, the
number of diagnoses reached 56 (18.5%) (incremental difference: 11.3% [95% CI:5.7%–16.9%] [p < 0.001]). Patients
with a CD4 cell count greater than 500 cells/μl and prior stay in prison were more likely to have a diagnosis of LTBI
by TST and/or QFG and/or T-SPOT.TB (adjusted odds ratio [aOR]: 3.8; 95% CI, 1.4 – 9.9; and aOR: 3.3; 95% CI,
1.3 – 8.3, respectively).
Conclusions: IGRAs were more sensitive than TST for diagnosis of M. tuberculosis infection in HIV-infected patients.
Dual sequential testing with TST and IGRAs may be the optimal approach for LTBI screening in this population.
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Background
Diagnosis and treatment of latent tuberculosis infection
(LTBI) is the most effective strategy to control tubercu-
losis (TB) among patients with HIV infection [1,2]. The
tuberculin skin test (TST), the only available method to
identify LTBI for more than a century, is known to have
major constraints [3], including a reduced sensitivity in
HIV-infected patients as compared with the general
population, particularly in those with low CD4 cell
counts [4].
The development of in vitro blood tests to evaluate
cell-mediated immune response against Mycobacterium
tuberculosis (M. tuberculosis) has been a major advance
for the diagnosis of LTBI. The interferon-gamma release
assays (IGRAs) measure T-cell release of interferon-γ
(IFN-γ) following stimulation by antigens that are
unique to M. tuberculosis including early-secreted anti-
genic target 6 (ESAT-6) and culture filtrate protein 10
(CFP-10), which are encoded by genes located within
the region of difference 1 (RD1) segment of the M. tu-
berculosis genome [5]. These antigens are more specific
for M. tuberculosis than those in the purified protein
derivate (PPD) used in the TST because they are not
shared with any BacilleCalmette-Guérin (BCG) vaccine
strains. However, at least 3 species of nontuberculous
mycobacteria also have the RD1 antigens as M. kansasii,
M. marinum and M. szulgai. QuantiFERON-TB Gold
In-Tube test (QFG) (Cellestis, Carnegie, Australia) mea-
sures the level of soluble IFN-γ produced in whole blood
by enzyme-linked immunosorbent assay (ELISA), and
the T-SPOT.TB (Oxford Immunotec, Abingdon, UK)
assay detects the number of IFN-γ -producing cells
represented as spot-forming units (SFU). The IGRAs
present practical and theoretical advantages over TST,
and the US Centers for Disease Control (CDC) have
released guidelines for using these assays to detect M.
tuberculosis infection in certain circumstances [6].
Published data on the performance of the IGRAs in
patients with HIV infection are limited and discordant [7-
10]. Moreover, only a few studies have compared both
IGRAs with TST in the diagnosis of LTBI among HIV-
infected individuals [11-13]. To determine the real per-
formance of these tests for the diagnosis of LTBI in
HIV-infected patients, large studies that include a con-
secutive series of patients with a broad spectrum of HIV
disease should ideally be performed. Given the reduced
sensitivity of TST in those patients, evaluating the contri-
bution of IGRAs to conventional TST is critical to decide
if these tests should be incorporated into clinical practice
in HIV medicine. To our knowledge, there is little infor-
mation. The aim of the present work was to evaluate the
usefulness of the IGRAs in a diverse cohort of HIV-
infected patients. In this investigation, patients with differ-
ent stages of HIV disease were studied to assess the tests,
and the characteristics of patients that provided a positive
IGRAs result were carefully examined.
Methods
Patients and samples
Patients were recruited into the study at the outpatient
HIV clinic of a university hospital (Hospital General
Universitario de Elche, Alicante, Spain). Eligible patients
were all HIV-infected adults (age ≥ 15 years) cared for in
the clinic from January 2009 to October 2010. The study
was approved by the Ethics Committee of Hospital Gen-
eral Universitario de Elche, and all the patients gave
their written informed consent.
Demographical and clinical data including age, sex, na-
tionality, HIV transmission route, years from diagnosis
of HIV infection, CDC category, AIDS events, and anti-
retroviral treatment (ART) received prior to the study
were recorded from the patients. Details were taken of
previous treatment for positive TST or past or current
TB, BCG vaccination status, history of household con-
tact with TB cases, intravenous drug use, and history of
previous stay prison or drug rehabilitation unit. Data
were also collected about immunologic status (nadir
CD4 cell count, CD4 cell count and percentage at the
time of evaluation) and plasma HIV-1 RNA viral load.
The past TB was referred by the patient or collected
from clinical records. Current TB diagnosis was based
on the results of clinical and radiologic examination
and/or isolation of M. tuberculosis from sputum or other
specimen (urine, lymph node and cerebrospinal fluid).
LTBI was defined by a previous positive TST performed
in our clinic or in another clinic.
Procedures
Blood samples were collected for measurement of the
IGRAs tests QFG and T-SPOT.TB and a conventional
TST was performed simultaneously in a blinded fashion.
Study participants were injected with 0.1 ml of tubercu-
lin (2 tuberculin units of PPD) (Tuberculina PPD; Evans
2UT, UCB Pharma, S.A. Madrid, Spain) in accordance
with the American Thoracic Society guidelines [14]. The
skin induration was measured with a rule at 48-72 hours
after the inoculation. The size of the induration equal or
higher than 5 mm was considered positive. The previous
BCG vaccination did not change the size limits for the
tuberculin reaction. The result was considered to be in-
valid or not read, if the patient did no come to measure
the induration and was impossible to contact him/her.
All patients with a positive tuberculin test who had not
been previously treated, received chemoprophylaxis with
isoniazid for 6-9 months. Patients with a positive IGRA
plus a positive TST also received isoniazid chemo-
prophylaxis. Their doctors in charge, who decided to
start chemoprophylaxis or not according to additional
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accompanying factors individually managed patients
with a positive IGRA, but negative TST.
For QFG, whole blood was collected from each patient
and inoculated in three heparinized tubes of 1 ml each:
one containing TB antigens (ESAT-6, CFP-10, and TB7.7),
a positive control tube containing phytohemagglutinin,
and a null control. Blood samples were incubated for 16-
20 h at 37°C. Plasma samples were then harvested for
IFN-γ quantification by a single-step sandwich-type
ELISA. The test was performed according to manufac-
turer’s instructions (Cellestis, Carnegie, Australia) [15].
Optical densities were interpreted using specific software
provided by the manufacturer. The result was considered
to be positive if the IFN-γ level after stimulation with TB
antigens minus negative control was ≥ 0.35 IU/ml and
≥ 25% of the negative control. The test was considered
negative if the IFN-γ level was < 0.35 IU/ml (after sub-
traction of the negative control). The test result was con-
sidered to be indeterminate if (1) the negative control was
≥ 8.0 IU/ml or (2) the positive control was < 0.5 IU/ml.
The T-SPOT.TB test was performed according to the
recommendations of the manufacturer (Oxford Immu-
notec, Abingdon, UK) [16]. We use T-Cell Xtend (Ox-
ford Immunotec, Abingdon, UK) reagent that is added
to blood samples in the laboratory immediately before
running the T-SPOT.TB assay. It allows blood samples
to be processed up to 32 hours after venopuncture
without affecting the accuracy of the test. Concisely,
peripheral blood mononuclear cells were spared by
centrifugation from an 8 ml heparinized blood sample
and then placed into four wells (2.5x105 cells per well).
The wells were stimulated with 50 μL each of phytohem-
agglutinin (positive control), ESAT-6, CFP-10, and
AIMW V medium (Invitrogen. USA) (negative control).
The wells were incubated for 16-20 h at 37°C in 5%
CO2, washed, and developed with a conjugate against
the antibody used and an enzyme substrate. The SFUs
were counted with an USB Microscope (MicroCapture)
[17], by one observer in case of doubt by two obser-
vers. The results of T-SPOT-TB were interpreted
according to the following criteria:
(1)Manufacturer’s criteria [16]. A result was considered
to be positive if the number of SFUs was > 5 (after
subtraction of the SFUs of the negative control). If
the negative control well was between 6 and 9 SFUs,
the result was considered positive if the number of
SFUs in the antigen well was > 2 x SFUs negative-
control. The test result was considered to be
negative if the above criteria were not met and the
positive control was valid. The result was considered
to be invalid if the SFUs of the negative control was
>10 or if the SFUs of the positive control well was
< 20 SFUs.
(2)Food and Drugs Agency (FDA) of the US criteria
[18]. These interpretation criteria included a
borderline interpretation. A result was considered to
be positive if the number of SFUs was ≥ 8 (after
subtraction of the SFUs of negative control). The
result was considered borderline if SFUs was equal
to 5, 6 or 7. The result was considered negative if
the number of SFUs was ≤ 4. The result was
considered to be invalid if the number of SFUs of
negative control was >10 or if < 20 SFUs in the
positive control well.
Statistical analysis
Data were analyzed using the SPSS software package ver-
sion 12.0 (SPSS Inc., Chicago, Illinois, USA). Concordance
between dichotomized TST, QFG and T-SPOT.TB was
assessed by kappa (κ) coefficient. Strength of agreement
was considered ‘poor’ for κ ≤ 0.20, ‘fair’ for 0.20 < κ ≤
0.40, ‘moderate’ for 0.40 < κ ≤ 0.60, ‘substantial’ for
0.60 < κ ≤ 0.80, and ‘optimal’ for 0.80 < κ ≤ 1.00 [19]. For
the analysis of agreement indeterminate and invalid tests
results were excluded.
Fisher’s exact test, Chi-square for lineal association,
Mc Nemar’s test, and Kruskal-Wallis test were used for
comparisons where appropriate. Significant univariate
predictors (P < 0.05) were included in a logistic regres-
sion model to identify independent predictors measured
by odds ratio (adjusted odds ratio, [aOR]) with the 95%
confidence interval (CI). We calculate the lower and
upper limits of the 95% CI for a proportion and the z-




The three tests, QFG, T-SPOT.TB and TST, were per-
formed in 373 subjects: Demographic and clinical char-
acteristics of these patients are summarized in Table 1.
The majority of patients were Spanish (92.5%); 187
(50.1%) had history of intravenous drug use, and 144
(38.6%) had a prior AIDS-defining event. Most of them
(74.5%) were on ART.
The median HIV-1 RNA viral load was <50 copies/ml
(range, <50 – 1 x 106); 218 (58.4%) patients had HIV-1
RNA viral load < 50 copies/ml. The median CD4 cell
count was 470 cells/μl (range, 10–1760/μl); 62 (16.6%)
individuals had CD4 cell count < 200 cells/μl. There
were 71 patients with either: a history of previously ac-
tive TB (n = 50), a history of previous treatment for
LTBI (n = 15), and current active TB (n = 6). Table 1
shows the differences between those patients without
and with past (n = 50) TB or current TB (n = 6) or pre-
vious positive TST treated (n = 15).
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Diagnostic tests
A TST result was not available in 28 (7.5%) of 373
patients, the reason being in all the cases that the patient
did not come to measure the induration, and it was im-
possible to contact him/her. In 13.3% (46/345) patients
the TST was positive (induration of at least 5 mm). QFG
was positive in 7.5% (28/373) patients. T-SPOT.TB was
positive in 18.5% (69/373) patients according to manu-
facturer’s criteria. When T-SPOT.TB results were cate-
gorized according to FDA’s criteria, 13.4% (50/373)
patients gave a positive result, and 7.2% (27/373) a bor-
derline result. In the Figure 1 shows a Venn diagram
where the various tests coincide in terms of positives
as defined by the manufacturers. QFG and T-SPOT.
TB were more often positive in patients with past or
current TB or previous treatment for positive TST and
in patients with contact with TB patients as summarized
in Table 2.
TST, QFG and T-SPOT.TB were positive in 13.3%,
7.5% and 18.5% cases; respectively. The number of inde-
terminate or invalid results was lower for QFG than for
T-SPOT.TB (2.7% versus 7.2%; p = 0.002). An indeter-
minate QFG result was statistically associated with CD4
cell count < 200/μl (8.1% versus 1.6%; p < 0.001). No
Table 1 Baseline demographic and clinic characteristics of 373 HIV-infected patients undergoing tuberculin skin test,
QuantiFERON-TB Gold and T-SPOT-TB testing, stratified according to past or current tuberculosis (TB) and previous





TB (n = 56)
Patients with
positive TST




TST (n = 302)
P value*
Demography
Median age, years (range) 44 (15-85) 45 (21-74) 42 (27-50) 44 (15-85) NS
Sex, male 287 (76.9) 44 (78.6) 14 (93.3) 229 (75.8) NS
Origin from a country with
high prevalence of TB
28 (7.5) 7 (12.5) 1 (6.7) 20 (6.7) NS
HIV-related factors
Prior AIDS defining illness 144 (38.6) 50 (89.3) 4 (26.7) 92 (30.5) <0.001
Median CD4 cell count,
cells/μl (range)
470 (10-1760) 350 442 (120-1200) 500 (10-1760) 0.02
(10-1550)
CD4 cell count < 200/μl 62 (16.6) 20 (35.7) 3 (20) 39 (12.9) <0.001
CD4 cell count < 350/μl 135 (36.2) 28 (50) 9 (60) 101 (33.4) 0.03
CD4 cell count < 500/μl 198 (53.1) 35 (62.5) 10 (66.7) 153 (50.7) 0.07
Median nadir CD4 cell count,
cells/μl (range)
150 (5-1650) 70 (5-1220) 240 (42-500) 180 (5-1650) <0.001
Median HIV-1 ARN viral load,
copies/ml (range)
<50 (0-1 x 106) 115 (0-1 x 106) <50 (0-85486) <50 (0-1 x 106) NS
HIV-1 RNA viral load
< 50 copies/ml
218 (58.4) 35 (49.3) 11 (74) 183 (60.6) NS
ART-naïve 95 (25.5) 24 (42.8) 13 (86.7) 77 (25.5) NS
Median time (years) since
1st HIV-positive test (range)
10 (0-27) 12 (0.1-22) 12 (3-24) 10 (0.1-27) 0.001
BCG vaccine 58 (15.8) 13 (23.2) 5 (33.3) 40 (13.9) 0.02
Risk factors for TB infection
Contact with patients with TB 144 (38.7) 40 (71.4) 11 (17.3) 93 (30.9) <0.001
History of injection drug use 187 (50.1) 35 (62.5) 14 (93.3) 138 (45.7) 0.001
History of prior prison stay 102 (27.3) 29 (51.8) 13 (86.7) 60 (19.9) <0.001
Lived in a shelter or homeless 97 (26.0) 22 (39.2) 6 (40) 66 (21.9) <0.001
Diabetes mellitus 16 (4.3) 1 (1.1) 1 (6.7) 14 (4.6) NS
Others
Hepatitis C virus co-infection 167 (45.1) 33 (58.9) 14 (93.3) 120 (40.0) <0.001
NOTE. Data are no (%) of patients unless otherwise indicated; ART, antiretroviral therapy; BCG, Bacille Calmette-Guérin; * p-value compared the patients with past
or current TB and previous positive TST with patients with no past or current TB nor positive TST.
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association of low CD4 cell count with indeterminate
T-SPOT.TB results was found.
Table 3 illustrates the concordance between TST, QFG
and T-SPOT.TB results stratified according to medical
history of past or current TB or previous treatment for
positive TST. Overall, agreement between TST and the
IGRAs was moderate or poor. It was higher in patients
with past or current TB or previous treatment for LTBI,
in whom the tests were more likely to be positive. Of
note, there was poor concordance between the two
IGRAs (κ = 0.351), particularly when using the manufac-
turer’s interpretation criteria for T-SPOT.TB.
Contribution of IGRAs to the diagnosis of LTBI
To assess the contribution of IGRAs to the diagnosis of
LTBI, only 302 patients with no past or current TB nor
previous treatment for positive TST were analyzed. A TST





















Figure 1 Venn diagram illustrating how often the tuberculin
skin test (TST), QuantiFERON-TB Gold (QFG), and T-SPOT.TB
tests coincide in terms of positives as defined by the
manufacturers in 372 HIV-infected patients (A) and in 302
HIV-infected patients with no past or current TB nor treated for
of latent tuberculosis infection (B).
Table 2 Comparison of tuberculin skin test (TST), QuantiFERON-TB Gold (QFG), and T-SPOT.TB in all the patients, in
patients with past or current tuberculosis (TB) or previous positive tuberculin skin test (TST) and in patients with no
past or current TB nor treatment for LTBI with and without TB contact
Test Patients Results of Test
Positive Borderline Negative Indeterminate or
invalid
TST All patients (n = 373) 46 (12.3) - 299 (80.2) 28 (7.5)
Patients with past or current TB or positive TST (n = 71) 26 (36.6) - 42 (59.2) 3 (4.2)
Patients with no past or current TB nor positive TST
without TB contact (n = 209)
7 (3.3) 188 (90.0) 14 (6.7)
Patients with no past or current TB nor positive TST
with TB contact (n = 93)
13 (14.0) - 69 (74.2) 11 (11.8)
QFG All patients (n = 373) 28 (7.5) - 335 (89.8) 10 (2.7)
Patients with past or current TB or positive TST (n = 71) 15 (21.1) - 56 (78.9) 0 (0)
Patients with no past or current TB nor positive TST
without TB contact (n = 209)
6 (2.9) 198 (94.7) 5 (2.4)
Patients with no past or current TB nor positive TST
with TB contact (n = 93)
7 (7.5) - 81 (87.1) 5 (2.4)
T-SPOT.TB (Mc) All patients (n = 373) 69 (18.5) - 278 (74.5) 26 (7.0)
Patients with past or current TB or positive TST (n = 71) 27 (38.0) - 40 (56.3) 4 (5.6)
Patients with no past or current TB nor positive TST
with TB contact (n = 209)
28 (13.4) 166 (74.4) 15 (7.2)
Patients with no past or current TB nor positive TST
with TB contact (n = 93)
14 (15.1) - 72 (77.4) 7 (7.5)
T-SPOT.TB (FDAc) All patients (n = 373) 50 (13.4) 27 (7.2) 270 (72.4) 26 (7.0)
Patients with past or current TB or positive TST (n = 71) 22 (31.0) 7 (9.9) 38 (53.5) 4 (5.6)
Patients with no past or current TB nor positive
TST without TB contact (n = 209)
20 (9.6) 12 (5.7) 162 (77.5) 15 (7.2)
Patients with no past or current TB nor positive TST
with TB contact (n = 93)
8 (8.6) 8 (8.6) 70 (72.9) 7 (7.5)
NOTE. Data are no (%) of patients unless otherwise indicated.
Mc: Manufacturer’s interpretation criteria; FDAc: Food and Drug Agency’s interpretation criteria.
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was obtained in 7.2% (20/277). In the Figure 2 shows how
often the various tests coincide in terms of positives in
these 302 patients. When, we added QFG results to TST,
there were a total of 26 (8.6%) diagnoses of LTBI (incre-
mental difference: 1.4% [95% CI: -3.1% – +5.7%] [p = 0.5]).
When adding T.SPOT.TB results interpreted according to
manufacturer’s criteria, the number of cases of LTBI
increased to 54 (17.9%) (incremental difference: 10.7%
[95% CI: 5.3%-16.2%] [p < 0.001]), and when both QFG
and T-SPOT.TB interpreted according to manufacturer’s
criteria were added, the number of diagnosis of LTBI
reached 56 (18.5%) (incremental difference: 11.3% [95%
CI: 5.7% – 16.9%] [p < 0.001]). When the more restricted
T-SPOT.TB FDA´s interpretation criteria were used, the
number of diagnosis of LTBI was 40 (13.2%) (incremental
difference: 6.0% [95% CI: 0.8% - 8.2%] [p = 0.02]), and after
considering both QFG and T-SPOT.TB interpreted
according to FDA´s criteria, it was 42 (14.6%) (incremen-
tal difference: 6.7% [95% CI: 1.4% – 11.9%] [p = 0.009]).
Factors associated with LBTI diagnosis by TST, QFG or T-
SPOT.TB
Table 4 shows the significantly factors associated with
LBTI diagnosed by TST and/or IGRAs. Compared with
patients with a TST negative, a LBTI diagnosis by a TST
positive (n = 20) was more common in those with a higher
median current CD4 (630 [range, 90-1650] versus 480
[10-1760]) (p = 0.02), a longer time from the first HIV-
positive test (11.5 [range, 0.1-27] versus 10 [range, 0-25])
(p = 0.04), and in those with history of contact with
patients with TB (65% versus 28.5%) (p = 0.002), history of
injection drug use (75% versus 43.6%) (p = 0.02), prior
prison stay (60% versus 17%) (p < 0.001), those living in a
shelter or being homeless (55% versus 19.5%) (p < 0.001),
and with hepatitis C virus co-infection (70% versus
37.9%) (p = 0.009). In logistic regression analysis, a
history of contact with patients with TB (aOR 4.6; CI
95%: 1.18-18.5) and prior prison stay (aOR 4.4; CI
95%: 1.18 – 18.7) were independently associated with a
positive TST.
A statistically significant association was found be-
tween a LTBI diagnosis by either TST or QFG or T.
SPOT.TB and a higher median current CD4 (580
[range, 10-1730] versus 450 [range, 10-1760] (p = 0.02),
a CD4 cell count greater than 500 cell/μl (67.9% versus
45.1%) (p = 0.002), longer time from the first HIV-
positive test (12 [range, 0.1-27] versus 9.5 [range, 0.1-23]
years) (p = 0.04), history of contact with patients with
Table 3 Concordance between tuberculin skin test (TST), QuantiFERON-TB Gold (QFG) and T-SPOT.TB in all the
patients, in patients with past or current tuberculosis (TB) or previous treatment for latent TB infection (LTBI), and
patients with no past or current TB nor treatment for LTBI
All patients Patients with past or current
TB or treatment for LTBI
Patients with no past or current
TB nor treatment for LTBI
QFG *vs TST* 0.548 0.524 0.437
(0.417-0.621) (0.359-0.615) (0.233-0.663)
T.SPOT.TB (Mc)* vs TST* 0.397 0.415 0.238
(0.268-0.515) (0.233-0.663) (0.092-0.392)
T.SPOT.TB (FDAc)** vs TST* 0.483 0.493 0.359
(0.339-0.609) (0.249-0.685) (0.176-0.541)
T.SPOT.TB (FDAc)*** vs TST* 0.392 0.482 0.237
(0.269-0.500) (0.243-0.665) (0.100-0.372)
T.SPOT.TB (FDAc)**** vs TST* 0.455 0.430 0.350
(0.315-0.583) (0.186-0.622) (0.171-0.533)
T.SPOT.TB (Mc)* vs QFG* 0.365 0.331 0.324
(0.255-0.437) (0.110-0.483) (0.196-0.381)
T.SPOT.TB (FDAc)** vs QFG* 0.478 0.456 0.426
(0.348-0.554) (0.213-0.601) (0.259-0.504)
T.SPOT.TB (FDAc)*** vs QFG* 0.351 0.355 0.289
(0.250-0.411) (0.143-0.477) (0.171-0.341)
T.SPOT.TB (FDAc)**** vs QFG* 0.464 0.447 0.414
(0.336-0.560) (0.208-0.611) (0.245-0.515)
NOTE. Data are kappa (κ) coefficient and lower and upper limits of the 95% confidence interval.
Mc: Manufacturer’s interpretation criteria; FDAc: Food and Drug Agency’s interpretation criteria.
*Excluding indeterminate results; ** excluding invalid and borderline results; *** excluding invalid results and borderline results considered as positive; ****
excluding invalid results and borderline results considered as negative.
Ramos et al. BMC Infectious Diseases 2012, 12:169 Page 6 of 10
http://www.biomedcentral.com/1471-2334/12/169
TB (42.9% versus 28.2%) (p = 0.04), history of injection
drug use (58.8% versus 42.7%) (p = 0.04) and prior
prison stay (37.1% versus 17.9%) (p = 0.002). In logistic
regression analysis, patients with a CD4 cell count
greater than 500 cells/μl and prior stay in prison were
more likely to have a diagnosis of LTBI (aOR 3.8; CI
95%: 1.4 – 9.9, and aOR 3.3; CI 95%: 1.3 – 8.3,
respectively).
Figure 2 Flow chart illustrating early and final diagnosis of latent tuberculosis (TB) infection (LTBI) in 302 HIV-infected patients with no
past or current TB nor treated for LTBI when adding QuantiFERON-TB Gold (QFG) and T-SPOT.TB to tuberculin skin test (TST).
Table 4 Significant variables associated with latent tuberculosis infection (LTBI) stratified by tuberculin skin test (TST)
or interferon-gamma release assays in 302 HIV-infected patients with no past or current tuberculosis (TB) nor LTBI






(n = 20) * (Mc) positive (Mc) positive
(n = 45) ** (n = 56) *** (n = 246)
Median CD4 cell/μl count (range) 630 (90-1650)† 580 (10-1740) { 580 (10-1730) † 450 (10-1760)
CD4 cell count < 350/μl 4 (20) 9 (20)¢ 13 (23.2) 88 (35.8)
CD4 cell count < 500/μl 6 (30) 12 (26.5) { 18 (32.1) } 135 (54.9)
Median time (year) from
1st HIV-positive test (range)
11.5 (0.1-27) †† 12 (0.1-25) c 12 (0.1-27) †† 9.5 (0.1-23)
Contact with patients with TB 13 (65) } 4 (8.9) 24 (42.9) †† 69 (28.2)
History of injection drug use 15 (75) † 24 (53.3) 33 (58.8) †† 105 (42.7)
History of prior prison stay 12 (60) { 24 (53.3) 21 (37.1) } 39 (17.9)
Lived in a shelter or homeless 11 (55) { 10 (25.2) 18 (32.1) 48 (19.5)
Hepatitis C virus co-infection 14 (70) ¢ 20 (44.5) 28 (50.0) 92 (37.7)
NOTE. Data are no (%) of patients unless otherwise indicated.
ART, antiretroviral therapy; BCG, Bacille Calmette-Guérin; QFG, QuantiFERON-TB Gold, Mc: Manufacturer’s interpretation criteria.
The numbers printed in bold letters indicate the value of variables significantly associated with positive test results in univariate analyses: †† p = 0.04; † p = 0.02 }
p = 0.002; ¢ p = 0.009; { p < 0.001; * comparing TST positive (n = 20) with TST negative patients (n = 282); ** comparing QFG or T.SPOT.TB positive (n = 45) with
QFG or T.SPOT-TB (Mc) negative patients (n = 257); *** comparing either TST, QFG or T-SPOT.TB (Mc) positive (n = 56) with all tests (TST, QFG and T.SPOT.TB-Mc)
negative (n = 246).
Ramos et al. BMC Infectious Diseases 2012, 12:169 Page 7 of 10
http://www.biomedcentral.com/1471-2334/12/169
Discussion
To our knowledge this is the largest study to date to
evaluate QFG and T-SPOT.TB tests and to define its
usefulness, compared with that of TST, in the diagnosis
of LTBI in HIV-infected patients in a middle-low TB in-
cidence setting. We found that IGRAs were more sensi-
tive than TST for the diagnosis of M. tuberculosis
infection. T-SPOT.TB test gave the largest number of
positive results using either manufacturer’s criteria or
FDA’s criteria. Noteworthy, T-SPOT.TB was positive in
many patients with a negative TST result, thus indicat-
ing that dual sequential testing with TST and IGRAs
may be the optimal approach for LTBI screening in
HIV-infected patients. Previous studies had shown that
IGRAs have higher specificity than TST in low TB inci-
dence settings [7,9,10,12,13,20], but did not specifically
assess the contribution of IGRAs to the diagnosis of
LTBI in patients with HIV infection. Therefore, this
study expands upon the evaluation of IGRA and offers
relevant information on its potential clinical usefulness.
As found in previous studies performed in HIV-
infected patients [10,12,13,21], agreement between the
IGRA tests and TST was moderate or poor, and indeter-
minate test results occurred in a significant proportion
of the patients. As expected [12,13], a higher rate of in-
determinate results was found with the T-SPOT.TB test
than with QFG. In agreement with previous studies
[12,13,20] indeterminate results of QFG were associated
with CD4 count of < 200 cell/μl, while the same did not
occur for T-SPOT.TB test. By contrast, indeterminate
results for T-SPOT.TB have been related to older age
and conditions of transportation [22].
In our study, T-SPOT.TB outperformed QFG. The
proportion of individuals testing positive has also been
found significantly greater with T-SPOT.TB than with
QFG in other studies conducted in asymptomatic HIV-
infected patients [11-13,20]. The higher performance of
T-SPOT.TB with respect to QFG is in line with previous
data indicating that T-SPOT.TB may be less affected by
advanced immunosuppression [21,23], and supported by
investigations conducted in persons with culture-
confirmed active TB [24,25]. In a recent meta-analysis,
pooled sensitivity estimates in culture-confirmed active
TB were higher for T-SPOT.TB than for QFG [21]. In
studies carried out in countries with low prevalence of
TB, sensitivity was 94% for T-SPOT.TB [24]. In the
study of Sauzullo et al the sensitivity of QFG was 67%,
not higher than that of TST in head-to-head comparison
[25]. It should be stated, however, that we did not use
the most reliable method for counting SFU, the auto-
mated ELISPOT plate reader, and therefore misclassifi-
cation of some of our results can not be ruled out.
Studies evaluating new laboratory techniques used for
the diagnosis of LTBI face a major challenge, which is the
lack of a satisfactory “gold standard” for assessing both
sensitivity and specificity, particularly in HIV-infected
patients. The patients with past, current history of TB or
LTBI had a higher frequency of positive tests presumably
because of a persistent immune response. Those patients
were included in the study as “positive controls”, to assess
the yield and reliability of the tests in the subset of patients
who retained persistent immune response.
Whereas prospective cohort studies have shown that
persons with a positive TST result have an increased
risk of developing active TB compared with persons
with negative TST result [1,26], there is a general agree-
ment that TST has low sensitivity, and it is assumed
that TST positive cases represent only a portion of the
cases of LTBI. Based on the test-positive rate among
patients with culture-confirmed TB, IGRAs are consid-
ered to be more sensitive than TST [27]. Indeed, in our
cohort, T-SPOT.TB was more frequently positive than
TST, particularly in patients with no past or current TB
nor treatment for LTBI.
A number of studies have pointed out that IGRAs may
also have a higher specificity than TST for the diagnosis
of LTBI in low TB incidence settings and correlate better
with surrogate markers of M. tuberculosis exposure
[27,28]. Although data from large prospective cohort
studies evaluating the clinical impact and predictive
value of IGRA testing are currently lacking, available in-
formation suggests that these tests may predict the sub-
sequent development of active TB in certain patient
populations even better than TST [29,30]. In a recent
study in male patients with silicosis without clinical sus-
picion of active TB, past history of TB, and treatment
for LTBI, T-SPOT.TB outperformed TST in predicting
TB disease [29], and a recent meta-analysis that included
studies of HIV-infected and HIV–uninfected patients
found that IGRAs results are more strongly associated
with progression to active TB than TST results [30].
Interestingly, in our study, T-SPOT.TB increased the de-
tection of M. tuberculosis infection in patients with nega-
tive TST by 7.3% when using the FDA’s interpretation
criteria or by 11.9% according to the manufacturer’s inter-
pretation criteria. There is little information on the signifi-
cance of a positive IGRAs result with negative TST in
HIV-infected individuals. Four previous longitudinal stud-
ies have evaluated the ability of IGRAs to predict future
development of active TB in HIV-infected individuals and
all of them reported a higher risk of active TB in indivi-
duals with positive IGRAs results [24,31-33]. However, in
all of the 3 studies the duration of follow-up was limited
and had few incident cases of active TB [21]. Unfortu-
nately, our study design did not allow evaluating the clin-
ical impact of implementing IGRAs in LTBI screening,
neither the predictive value for active TB of a positive
IGRAs result in patients with TST negative. The rate of
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anergic patients was also unknown because no additional
skin tests to the TST were performed.
Conclusions
Our study suggests that IGRAs, particularly T-SPOT.TB,
may have a role for identifying M. tuberculosis infection in
HIV-infected individuals, and support a dual testing ap-
proach, starting with TST and performing T-SPOT.TB if
the TST is negative. Although we were unable to identify a
typical patient profile with TST negative but IGRAs posi-
tive, T-SPOT.TB is more likely to be useful in patients
with no past or current TB nor treatment for LTBI, a set-
ting in which sensitivity of T-SPOT.TB was twice that of
TST. Whether T-SPOT.TB truly identifies HIV-infected
individuals who would benefit from preventive therapy
remains unanswered. Further studies are required to es-
tablish the clinical impact and cost-effectiveness of dual
testing approaches in clinical practice.
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